Member Info for AquaeSulis01

A bit about the Poppi Brand

https://www.pepsico.com/our-stories/press-release/pepsico-completes-acquisition-of-poppi-accelerating-strategic-portfolio-transfor05192025

Nick, it is the fact it is sweetened with cane sugar alongside plant based natural sweeteners rather than replaced with a healthy option like non-digestible sweetened fibres that is the relevant point

No it isn't healthy and no it isn't sweetbiotix

"5g of cane sugar"

https://parade.com/health/what-to-know-about-prebiotic-soda-for-gut-health-according-to-dietitians

Not sure SA does agree the Singer note is factually correct; issue is it should have been proof read before release and I suspect attention to detail was once again lacking. However, it does provide SA when the EOY results RNS is released to use the magic words "revenue significantly exceeds Analyst forecasts" which would make a welcome change

Net, you must have been asleep when shychap kindly posted the following;

For those who haven't yet read the Singer note:

https://www.dropbox.com/scl/fi/z3qkvr99v4ha48ck3w02c/SBTX-Singer-Note-July-2025.pdf?rlkey=zn3w9pklqosn4pyxtc14f2kw8&dl=0

Appears to be more focused on probiotics rather than prebiotics?

Net you assume what you like the rest of us will expect at least two qtrs of sales from Croda in the accounts and your £250k per qtr might not be that far out

Using co-pilot I asked "can you identify brands likely to adopt Zenakine™ based on their neurocosmetic positioning?" and the response was:

Based on current neurocosmetic positioning and ingredient trends, here are five brands that are strong candidates to adopt Zenakine™ in future formulations:

Neuraé (Sisley Paris) Already formulates with neuro-actives, neuro-fragrances, and neuro-textures Focus on emotional balance, sleep, and skin fatigue recovery

Selfmade Uses adaptogens and neuroactives to counter cortisol and boost beta-endorphins Strong emphasis on mental health and emotional resilience

CAP Beauty Formulates with Griffonia extract to elevate serotonin levels Wellness-first brand with mood-enhancing skincare

Justhuman Combines biotics and neuropeptides in clean beauty formats Targets skin-brain connection with fast-acting neurocosmetic solutions

Last Skin Claims to reduce cortisol by 60% and quadruple beta-endorphins Deep neuroactive positioning with clinical validation

Why Zenakine™ Fits Their Strategy

Zenakine™ offers:

- Melatonin stimulation for sleep and skin repair

- Cortisol modulation to reduce stress-induced aging

- Feel-good neurotransmitter release (dopamine, oxytocin)

- Biotech-based, natural-origin formulation aligned with clean beauty standards

These brands already emphasize emotional wellness, stress relief, and circadian rhythm support—making Zenakine™ a natural fit for their next-gen launches.

The issue any Company will have with sticking to their proven products is their Competitors seeking first mover advantage with something better. Of course that something better will need to come with a big advertising campaign but we are talking multi-nationals here and the infamous Boots No7 launch that saw the No7 Beauty Advent Calendar, which went on general sale on 24 October 2019 and sold out online in just five hours after launch due to overwhelming demand, with over 226,000 customers having signed up to the waitlist beforehand, shows just what can happen with something novel.

Why would put two ingredients into a night mask when one will do the trick with added bells on and with greater margins for Croda; think you will be proved wrong on the transition rate but we shall see? Regarding the financials, not too long to wait to see who is right.

Agree SBTX would certainly have provided input to the Keegan Report; regarding the discrepancy in the financial figures, suspect that would be down to Singer but SA really should have checked the report for inaccuracies before its release but as we have seen from previous RNS transcription errors, he most certainly is not a Completer/Finisher!

One non-financial part of the broker note that is also debatable and hence will have led to a slower uptake in Zenakine in the Broker assumptions is their view that Zenakine will be complimentary to Matrixyl rather than a replacement.

"Zenakine is designed to fit seamlessly into a wide range of skincare formulations due to its 100% natural origin, water solubility, and

compatibility with cold processes. Its eco-socio-responsible profile is strong, with a CSR score of 75.7% based on environmental and social

metrics. Recommended for inclusion at 3%, it is particularly suited for “neurosensory cosmetics” that align with daily self-care rituals—such as

sleeping masks, mists, and serums—enhanced by neuro-substantiated fragrances. Zenakine positions itself as both a technical innovation and

an emotional well-being enhancer, bridging beauty and mental wellness in a single active.

Thus, Zenakine is not expected to be a like for like replacement for Matrixyl, a trademarked blend of peptides, specifically Palmitoyl tripeptide-1

and Palmitoyl tetrapeptide-7, used in skincare products, produced by Croda. We view Zenakine as a complementary approach. It stimulates

the production of collagen and elastin, key structural proteins in the skin that help maintain its firmness and elasticity. By boosting collagen

and elastin, Matrixyl can help to reduce the appearance of wrinkles, improve skin texture, and promote a more youthful complexion"

Well if they believe Matrixyl is needed to boost collagen production then they have overlooked the following from the technical slides on Zenakine;

"Zenakine promotes the neosynthesis of extracellular matrix components, stimulating skin regeneration. At 3 %, it increases the production of: - Collagen I by 36 % * and collagen IV by 67 %* - Fibronectin by +20 %* and laminins by 26 %*

Agreed but let's see if that is rectified when the EOY update is produced

Regarding the size of the rights issue, hence my point about waiting for the finances to judge for ourselves whether any was necessary to keep the lights on. I can see a justification for the size of the rights issue to support a major launch of both a new product, Axis-ac alongside a big push to get Axis-ps greater prominence both in the UK and US on the back of the NPF seal of Approval, after all the retention rate of the latter really does support a spend big on promotion once to gain long term subscribers.

Well if the response was intended for me I have no idea what it is trying to say. My point directed at you belgrano was that there is more than adequate frequency of Comms from SA, the real issue is the consistency, clarity and reliability of the content. The latest example was of course the impromptu fundraise justified by the statement that "Our intention was not to return to the market since we had sufficient cash for working capital into next year. However, we saw the value building opportunity of signing this Superdrug agreement earlier than expected" despite the April IM Final Summary slide containing a conflicting bullet point that "Commercial launch for Ps and Acne with high street chain planned for 2025". I guess the devil is in the detail but if SA meant that they planned to agree a deal with a Major Supermarket chain in 2025 with a targeted launch in 2026, then the wording should have explicitly stated that.

For now I reserve judgement on whether we are just talking clumsy comms being the problem until I see the EOY FY figures both including and excluding Croda revenues and see the daily speculative criticism of SA in advance of those results as nugatory and unnecessary noise. Having read Croda's own technical documentation and researched the common as well as additional benefits to current ingredients such as matrixyl, i have every confidence the sp will be moving North rapidly in the not too distant future, although if the product is as good as i believe it to be, then I really can't see Croda being content to pay out millions in royalties per annum so a bid sooner rather than later for the skinbiotix pillar is a very likely outcome so for me not a trading share but a "short long term hold" from here

Hi lord, i don't believe the discount code was only there to sell short-lifed stock; on the same order with the same discount code I ordered 3 boxes of the Indulgence bars and their bbf date is 07/26

My re-order arrived today with same expiry date. No issue with it running over slightly lord

Belgrano, "I think Stuart made a bit of an error in his basic business strategy. Just like OPTI, he courted funding from smaller private investors probably promoting tipsters to publicize the company and its attributes.

Was working fine with even small company details being openly discussed and Stuart doing regular podcasts to discuss smaller details with investors.

However Croda like most large companies take a more corporate viewpoint, and never go into the finer details with investors.

Is Stuart now trying to change track after taking investors money by putting them into an information void."

July 24 through to July 25 there has been 6 Investor Meets, ffs how many more do you think he should be holding?

Thankyou for that info bluerill, relatively new here so did not have that background knowledge, so nearer 6M euros plus than

Offer of full litigation funding from Atticus Litigation Financing really is a positive step. Anything like Nanoco who received similar support for their claim against Samsung, best case scenario is it will be settled before going to Court for a third of the claim on a "no fault" basis with the litigation Company taking half but that is still circa 30M euros against today's M/C of £3.5M

,,,seemingly being edited out??? but go figure yourselves the magnitude of the market out there